Literature DB >> 239966

Selective beta-1 receptor blockade with oral practolol in man. A dose-related phenomenon.

J J Lertora, A L Mark, J Johannsen, W R Wilson, F M Abboud.   

Abstract

The purpose of this study was to test the hypothesis that oral administration of a low dose of practolol in man produces selective beta-1 receptor blockade, whereas oral administration of a high dose blocks both beta-1 and beta-2 receptors. Normal men were studied 2-4 h after a single oral dose of practolol (1.5 or 12 mg/kg) and after placebo. Effects on beta-1 receptors were studied by measuring heart rate responses to exercise. Effects on beta-2 receptors were tested by measuring forearm vascular responses to brachial arterial infusions of isoproterenol. Neither dose of practolol altered base-line heart rate, forearm vascular resistance, and arterial pressure, Both low and high doses significantly attenuated heart rate responses to exercise. Forearm vasodilator responses to isoproterenol were attenuated by the high dose, but not the low dose, of practolol. Serum concentrations of practolol 2 h after administration of the drug and at the time of the studies of forearm vascular responses averaged 0.5+/-0.1 (SE) and 5.9+/-1.0 mug/ml for low and high doses of practolol, respectively. The results indicate that the phenomenon of selective beta-1 receptor blockade in man is related to the dose and serum concentration of practolol selectively block beta-1 receptors; a high dose and serum concentrations block both beta-1 and beta-2 receptors.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 239966      PMCID: PMC301921          DOI: 10.1172/JCI108143

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  EFFECT OF DICHLOROISOPROTERENOL ON VASCULAR RESPONSES TO CATECHOLAMINES IN MAN.

Authors:  F M ABBOUD; J W ECKSTEIN; B G ZIMMERMAN
Journal:  J Clin Invest       Date:  1964-02       Impact factor: 14.808

2.  A NEW ADRENERGIC BETARECEPTOR ANTAGONIST.

Authors:  J W BLACK; A F CROWTHER; R G SHANKS; L H SMITH; A C DORNHORST
Journal:  Lancet       Date:  1964-05-16       Impact factor: 79.321

3.  The measurement of volume changes in human limbs.

Authors:  R J WHITNEY
Journal:  J Physiol       Date:  1953-07       Impact factor: 5.182

4.  Correlation of beta blockade with serum practolol levels after oral administration.

Authors:  D W Schneck; V S Aoki; F W Kroetz; W R Wilson
Journal:  Clin Pharmacol Ther       Date:  1972 Sep-Oct       Impact factor: 6.875

5.  Selective beta adrenergic receptor antagonism in the anesthetized dog.

Authors:  M A Wasserman; B Levy
Journal:  J Pharmacol Exp Ther       Date:  1974-02       Impact factor: 4.030

6.  Cardiospecificity of -receptor blockade. A comparison of the relative potencies on cardiac and peripheral vascular -adrenoceptors of propranolol, of practolol and its ortho-substituted isomer, and of oxprenolol and its para-substituted isomer.

Authors:  E M Williams; E E Bagwell; B N Singh
Journal:  Cardiovasc Res       Date:  1973-03       Impact factor: 10.787

7.  Practolol in patients with angina pectoris.

Authors:  E L Alderman; R O Davis; J P Friedman; A F Graham; H J Matlof; D C Harrison
Journal:  Clin Pharmacol Ther       Date:  1973 Mar-Apr       Impact factor: 6.875

8.  Specific beta adrenergic blockade by practolol.

Authors:  M E Thompson; R H McDonald; D F Leon; J A Shaver
Journal:  Clin Pharmacol Ther       Date:  1974-11       Impact factor: 6.875

9.  Practolol in treatment of angina pectoris. A double-blind trial.

Authors:  C F George; R E Nagle; B L Pentecost
Journal:  Br Med J       Date:  1970-05-16

10.  Pharmacodynamic studies of beta adrenergic antagonism induced in man by propranolol and practolol.

Authors:  G Bodem; H L Brammell; J V Weil; C A Chidsey
Journal:  J Clin Invest       Date:  1973-04       Impact factor: 14.808

View more
  33 in total

Review 1.  Hypertension: which beta-blocker?

Authors:  H J Waal-Manning
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

Review 2.  Advancements in pharmacotherapy for angina.

Authors:  Ankur Jain; Islam Y Elgendy; Mohammad Al-Ani; Nayan Agarwal; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2017-03-15       Impact factor: 3.889

3.  A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Practolol inhibition of some salbutamol-induced metabolic and hormonal responses.

Authors:  F Massara; V Martina; V Fassio; S Sapelli; G Molinatti
Journal:  Acta Diabetol Lat       Date:  1977 Sep-Dec

6.  Current status of Beta blocker therapy.

Authors:  J D Gray
Journal:  Can Fam Physician       Date:  1980-05       Impact factor: 3.275

Review 7.  The assessment of beta-adrenoceptor blocking drugs in man.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

8.  beta-Adrenoceptor antagonists and respiratory function.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1978-02       Impact factor: 4.335

9.  Influence of environmental temperature and humidity on bronchial responses during assessment of selectivity of beta-adrenoceptor antagonists in man.

Authors:  E A Taylor; P W Trembath; S J Warrington
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

Review 10.  Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.

Authors:  A M Brooks; W E Gillies
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.